Mechanisms of NAFLD development and therapeutic strategies

By S. Friedman, B. Neuschwander‐Tetri, M. Rinella, A. Sanyal. Nature Medicine, 2018

3,682 citations recorded by the source corpus.

There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and liver cancer. Here we review the pathogenic and clinical features of NAFLD, its major comorbidities, clinical progression and risk of complications and in vitro and animal models of NAFLD enabling refinement of therapeutic targets that can accelerate drug development. We also discuss evolving principles of clinical trial design to evaluate drug efficacy and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression. Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials.

Subfields: Cell Biology, Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/f2ad04baf4dd9d29131c5df40f797e4eee5d063e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

  1. Christopher D. Byrne
  2. Herbert Tilg
  3. G. Targher

In Endocrinology, Diabetes and Metabolism

  1. Christopher D. Byrne
  2. Herbert Tilg
  3. G. Targher

In Epidemiology

  1. Christopher D. Byrne
  2. G. Targher
  3. Herbert Tilg

Citations in the corpus